BMI-1

Other Cell Cycle Related Inhibitors

CDK ROCK Wee1 Aurora Kinase Chk PLK APC MPS1 Rho Myc

Cat.No.	Product Name	Information	Product Use Citations
S7372	PTC-209	PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).	Int J Mol Med, 2025, 56(4)155 Anticancer Res, 2024, 44(12):5283-5292 Front Nutr, 2023, 10:1141964
S7539	PTC-209 HBr	PTC-209 HBr is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).	Nat Commun, 2023, 10.1038/s41467-023-42930-y Int J Biol Sci, 2022, 18(7):2807-2820 PLoS Pathog, 2022, 18(8):e1010801
S8820	Unesbulin (PTC596)	Unesbulin (PTC596) is a second-generation BMI-1 inhibitor that accelerates BMI-1 degradation. This compound downregulates MCL-1 and induces p53-independent mitochondrial apoptosis. IC50 values at 72 hours ranged from 68 to 340 nM in mantle cell lymphoma (MCL) cell lines.	Cell Rep Med, 2025, S2666-3791(25)00150-8 NPJ Precis Oncol, 2024, 8(1):68 PLoS One, 2023, 18(2):e0277313
S8662	PTC-028	PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification.	Sci Rep, 2025, 15(1):22917 NPJ Precis Oncol, 2024, 8(1):68
S5315	PRT4165	PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.	Nat Commun, 2023, 10.1038/s41467-023-42930-y Leukemia, 2021, 10.1038/s41375-021-01121-8 Leukemia, 2021, 10.1038/s41375-021-01121-8